Leuprorelin 3.75mg powder and solvent for suspension for injection vials
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Leuprorelin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Leuprorelin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
8 branded products available
Part of the Prostap brand family (generic: Leuprorelin)
MHRA licensed products
View all licensed products for Leuprorelin on the MHRA register
Lutrate 1 month Depot 3.75mg powder and solvent for suspension for injection vials
Prostap SR 3.75mg powder and solvent for suspension for injection vials
Prostap SR 3.75mg powder and solvent for suspension for injection vials
Prostap SR 3.75mg powder and solvent for suspension for injection vials
Prostap SR 3.75mg powder and solvent for suspension for injection vials
Mawdsley-Brooks & Company Ltd
Prostap SR 3.75mg powder and solvent for suspension for injection vials
WHO defined daily dose (DDD)
134 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Leuprorelin
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(7)
Linzagolix for treating symptoms of endometriosis (TA1067)
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
90 found
Half-life
Not available
Mechanism
Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
4-5 hours
[A203126]…
Half-life
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
Protein binding
43%
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
Volume of distribution
27 L
Metabolism
Elimination
3.75 mg
[L10310,…
Clearance
1 mg
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™ by Abbvie Endocrine Inc.[L13850] Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months.[L13781][L13790] Leuprolide remains frontline therapy in all conditions for which it is indicated for use.
[L13790]
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
[L13784][L13787]
In combination with oral [norethisterone] (also known as norethindrone), leuprolide is also indicated for the initial treatment of the symptoms of endometriosis.
[L10310]
Finally, in combination with iron supplementation, leuprolide is indicated for the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids).
[L13814]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1216 interactions
[A203126]
Prostate cancer patients treated with leuprolide at doses as high as 20 mg/day for two years showed no additional adverse effects compared to those receiving 1 mg/day.
[L13814]
Despite the variety of conditions indicated for treatment with leuprolide, the mechanism of action underlying efficacy is the same in all cases. As a GnRHR agonist, leuprolide binds to and initially activates downstream LH and FSH release; this initial spike in gonadotropin levels is responsible for some of the adverse effects associated with treatment. After 2-4 weeks of treatment, continuous stimulation of GnRHR results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.[A203126][A203129][A203132][A203222][L10310][L13781][L13784][L13787][L13790][L13814]
In women undergoing treatment for endometriosis or uterine leiomyomata, careful consideration regarding pregnancy status is advised. The initial increase in estradiol levels may worsen symptoms such as pain and bleeding. Long-term use of leuprolide is associated with loss of bone mineral density. Patients co-administered with [norethisterone] may experience sudden vision loss, proptosis, diplopia, migraine, thrombophlebitis, and pulmonary embolism and may also be at higher risk of cardiovascular disease. Patients with a history of depression may experience severe recurrence of depressive symptoms.[L10310][L13814]
In men undergoing palliative treatment for advanced/metastatic prostate cancer, short-term spikes in testosterone levels may cause tumour flare and associated symptoms such as bone pain, hematuria, neuropathy, bladder and/or ureteral obstruction, and spinal cord compression. In addition, patients are at increased risk of developing hyperglycemia, diabetes, and cardiovascular disease, which may manifest through myocardial infarction, stroke, cardiac death, or prolonged QT/QTc interval. In addition, Leuprolide may cause convulsions and embryo-fetal toxicity.[L13781][L13790]
In pediatric patients undergoing treatment for central precocious puberty (CPP), the initial steroidal spike may be associated with increased clinical signs of puberty within 2-4 weeks of treatment initiation. In addition, leuprolide may cause convulsions and psychiatric symptoms, including irritability, impatience, aggression, anger, and crying.[L13784][L13787]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A203126]
Regardless of the exact formulation and initial dose strength, the Cmax is typically achieved by 4-5 hours post-injection and displays large variability in the range of 4.6 - 212 ng/mL. Eventual steady-state kinetics are typically achieved by four weeks, with a narrower range of 0.1 - 2 ng/mL. No studies on the effects of food on absorption have been carried out.
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
[L10310][L13781][L13784][L13814]
[L10310][L13781][L13784][L13787][L13790][L13814][L34415]
Proteins and enzymes this drug interacts with in the body
ATC L02AE51
ATC L02AE02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Leuprolide
Matched from: Leuprorelin
Additional database identifiers
Drugs Product Database (DPD)
1756
Drugs Product Database (DPD)
23683
ChemSpider
571356
BindingDB
50369395
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4421
GenAtlas
GNRHR
GeneCards
GNRHR
GenBank Gene Database
L03380
GenBank Protein Database
183422
Guide to Pharmacology
256
UniProt Accession
GNRHR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4419
GeneCards
GNRH1
UniProt Accession
GON1_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
10 active patents, 24 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: